Market Access News | pharmaphorum

News

FDA clears BMS’ Breyanzi for follicular lymphoma

Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (

News

Updated BIOSECURE Act draft clears House committee

Legislation that would restrict US organisations from contracting with some Chinese biotech providers has been passed by a House of Representatives committee, moving close

News

Home testing devices for sleep apnoea backed for NHS use

Five home-testing devices for obstructive sleep apnoea hypopnoea syndrome (OSAHS), a potentially dangerous condition affecting 2.5 million adults in the UK, have been reco

News

Eisai, Biogen start delayed subcutaneous Leqembi filing

Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the

News

FDA clears Roche self-collection system for HPV screening

The US FDA has approved a human papillomavirus (HPV) self-sampling solution developed by Roche that allows patients to collect a sample themselves in a healthcare setting.

News

ICER raps conduct of Lykos’ psychedelic trial for PTSD

The Institute for Clinical and Economic Review (ICER) typically focuses on the cost-effectiveness of new therapies, but in an unusual move has sharply criticised the desig

FDA clears BMS’ Breyanzi for follicular lymphoma

Updated BIOSECURE Act draft clears House committee

Home testing devices for sleep apnoea backed for NHS use

Eisai, Biogen start delayed subcutaneous Leqembi filing

FDA clears Roche self-collection system for HPV screening

ICER raps conduct of Lykos’ psychedelic trial for PTSD

Euro VCs team up to invigorate life sciences ecosystem

How to meet your physicians where they are online

News

Editor's Picks